Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 17/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687674 | 0.89 | — | — | |
| SCHEMBL11043155 | 0.89 | EPHX2 (0.48) | EPHX2MMP2MMP8 | |
| SCHEMBL11043150 | 0.89 | EPHX2 (0.48) | EPHX2MMP2MMP8 | |
| Hydrochloric Acid SCHEMBL14917782 | 0.87 | — | — | |
| SCHEMBL16437081 | 0.86 | SMYD3 (0.36) | SMYD3EPHX2ROCK2MMP2MMP8 | |
| SCHEMBL16437117 | 0.86 | SMYD3 (0.36) | SMYD3EPHX2ROCK2MMP2MMP8 | |
| SCHEMBL23735494 | 0.82 | EPHX2 (0.61) | EPHX2MMP2MMP8 | |
| SCHEMBL1412068 | 0.82 | EPHX2 (0.61) | SMYD3EPHX2 | |
| SCHEMBL9003889 | 0.82 | EPHX2 (0.61) | SMYD3EPHX2 | |
| Cyclohexylamine SCHEMBL27893155 | 0.81 | EPHX1 (0.50) | EPHX2MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117887060-A | Amine polyether polyol and preparation method thereof | 山东一诺威新材料有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117887060-A | Amine polyether polyol and preparation method thereof | 山东一诺威新材料有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11548850-B2 | Development of a cofilin inhibitor for the treatment of hemorrhagic brain injury-induced neuroinflammation | THE UNIVERSITY OF TOLEDO (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200369603-A1 | Development of a Cofilin Inhibitor for the Treatment of Hemorrhagic Brain Injury-Induced Neuroinflammation | THE UNIVERSITY OF TOLEDO (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369603-A1 | Development of a Cofilin Inhibitor for the Treatment of Hemorrhagic Brain Injury-Induced Neuroinflammation | THE UNIVERSITY OF TOLEDO (US) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369603-A1 | Development of a Cofilin Inhibitor for the Treatment of Hemorrhagic Brain Injury-Induced Neuroinflammation | CFL1, NFKBIA, LIMA1 | SMYD3 2332/4885EPHX2 2447/4885ROCK2 12/4885 |
| US-11548850-B2 | Development of a cofilin inhibitor for the treatment of hemorrhagic brain injury-induced neuroinflammation | CFL1, NFKBIA, LIMA1 | SMYD3 2332/4885EPHX2 2447/4885ROCK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.